Latest Conference Articles

Merger of Two Groups Boosts Psychosocial Support Resources for Patients With Cancer

Merger of Two Groups Boosts Psychosocial Support Resources for Patients With Cancer

July 29th 2019, 6:05pm

ASCO Annual Meeting

The merging of MyLifeLine.org with Cancer Support Community facilitates more comprehensive social and emotional support for patients and caregivers affected by cancer.

Updated Analysis Supports Evaluation of Second-Line Fedratinib to Treat Myelofibrosis

Updated Analysis Supports Evaluation of Second-Line Fedratinib to Treat Myelofibrosis

July 24th 2019, 1:00am

ASCO Annual Meeting

Treatment with fedratinib may lead to clinically meaningful responses among patients with myelofibrosis who were previously treated with Jakafi, according to an updated analysis of the phase 2 JAKARTA2 study.

First-in-Class Drug Preserves Blood Counts During Chemotherapy for Lung Cancer

First-in-Class Drug Preserves Blood Counts During Chemotherapy for Lung Cancer

July 23rd 2019, 7:00pm

ASCO Annual Meeting

Given with each dose of chemotherapy, trilaciclib temporarily puts bone marrow to sleep, helping to prevent fevers, infections and hospital stays in patients with small cell lung cancer.

Ongoing Study Will Examine Cardiac Toxicity of Breast Cancer Treatment

Ongoing Study Will Examine Cardiac Toxicity of Breast Cancer Treatment

July 23rd 2019, 12:00am

ASCO Annual Meeting

Patients with breast cancer can still enroll in a clinical trial that is seeking to find the cause behind cardiac toxicity related to anthracycline-based treatment.

The Patient Voice Matters in Cancer Care

The Patient Voice Matters in Cancer Care

July 19th 2019, 5:00pm

ASCO Annual Meeting

Researchers examined what goes into treatment decision-making for patients with multiple myeloma.

With Addition of Checkpoint Inhibitors, Chemotherapy 'Not Going Away Anytime Soon'

With Addition of Checkpoint Inhibitors, Chemotherapy 'Not Going Away Anytime Soon'

July 17th 2019, 8:32pm

ASCO Annual Meeting

With new ways to treat chemotherapy-induced side effects, it seems that chemotherapy, combined with checkpoint inhibitors, is here to stay for the foreseeable future, according to one expert.

Combinations May Be the Future of Liver Cancer Treatment

Combinations May Be the Future of Liver Cancer Treatment

July 15th 2019, 10:05pm

ASCO Annual Meeting

With a wealth of drugs available for the treatment of liver cancer, one expert explained how combination therapy may be where the future is headed.

A Trial for Every Patient and a Patient for Every Trial

A Trial for Every Patient and a Patient for Every Trial

July 15th 2019, 6:42pm

ASCO Annual Meeting

One expert weighs the benefits and drawbacks of expanding clinical trials to be more inclusive and reflective of the general patient population with cancer.

What Patients Should Know About Genetic Testing and Hereditary Cancer Risk

What Patients Should Know About Genetic Testing and Hereditary Cancer Risk

July 15th 2019, 5:20pm

ASCO Annual Meeting

A breast cancer survivor and hereditary cancer expert discussed how patients can find accurate information about genetic mutations.

Practice-Changing Treatments for Bladder Cancer

Practice-Changing Treatments for Bladder Cancer

July 10th 2019, 9:17pm

ASCO Annual Meeting

A medical oncologist discusses the findings of three clinical trials presented during the 2019 American Society of Clinical Oncology Annual Meeting.

Future of Renal Cell Carcinoma: Hope Is on the Horizon

Future of Renal Cell Carcinoma: Hope Is on the Horizon

July 10th 2019, 6:05pm

ASCO Annual Meeting

One expert discusses the “extremely interesting and extremely dynamic” field of renal cell carcinoma, and how recent research and FDA actions could offer hope for patients and their doctors.

Limited Cancer-Related Fatigue Regression Highlights Need for Intervention

Limited Cancer-Related Fatigue Regression Highlights Need for Intervention

July 9th 2019, 5:00pm

ASCO Annual Meeting

While half of women with gynecologic cancer reported experiencing significant fatigue during treatment, only 8% of survivors had symptoms regress without intervention.

Pediatric Neuroblastoma Survivors Face Task Efficiency, Emotional Regulation Impairments

Pediatric Neuroblastoma Survivors Face Task Efficiency, Emotional Regulation Impairments

July 9th 2019, 12:00am

ASCO Annual Meeting

Long-term survivors of pediatric neuroblastoma may be at an increased risk for neurocognitive impairment – in particular, due to age at diagnosis and the type of treatment received.

App Helps Move Glioblastoma From 'Terminal to Treatable, Powered by Patients' Input

App Helps Move Glioblastoma From 'Terminal to Treatable, Powered by Patients' Input

July 8th 2019, 4:47pm

ASCO Annual Meeting

A glioblastoma (GBM)-specific app, called OurBrainBank, efficiently collected patients’ symptoms – offering many hope for future research, according to founder Jessica Morris.

Lung Cancer Stigmas Affect Patients Psychosocially, Lead to Worse Health Outcomes

Lung Cancer Stigmas Affect Patients Psychosocially, Lead to Worse Health Outcomes

July 5th 2019, 5:00pm

ASCO Annual Meeting

Studies show that the social stigma can actually affect a patient’s level of care and lead to worse health outcomes.

Adcetris Is a 'Good Treatment' for Patients With Advanced Hodgkin Lymphoma

Adcetris Is a 'Good Treatment' for Patients With Advanced Hodgkin Lymphoma

July 4th 2019, 5:00pm

ASCO Annual Meeting

A lymphoma expert discusses the side effect profile and follow-up data from the ECHELON-1 clinical trial.

Tumor Mutation Burden May Be Predictive of Depression in Patients With Lung Cancer

Tumor Mutation Burden May Be Predictive of Depression in Patients With Lung Cancer

July 3rd 2019, 9:00pm

ASCO Annual Meeting

Tumor mutation burden may be an independent predictor of developing depression in patients with lung cancer, according to Dr. Daniel McFarland.

Cell Therapies May Help Overcome Drug Resistance in Patients With Mantle Cell Lymphoma

Cell Therapies May Help Overcome Drug Resistance in Patients With Mantle Cell Lymphoma

July 1st 2019, 7:00pm

ASCO Annual Meeting

Breakthroughs such as CAR-T cell therapy in the treatment of mantle cell lymphoma could help patients overcome drug resistance and ultimately live longer, according to Dr. Michael Wang.

Telemedicine: A Growing Opportunity in Oncology

Telemedicine: A Growing Opportunity in Oncology

June 28th 2019, 5:00pm

ASCO Annual Meeting

The growing use of telecommunication and technology to provide health care – or telemedicine – offers many advantages, but also comes with challenges, says one expert.

Addition of Trilaciclib May Mitigate Myelosuppression in Patients With Small Cell Lung Cancer

Addition of Trilaciclib May Mitigate Myelosuppression in Patients With Small Cell Lung Cancer

June 28th 2019, 4:00pm

ASCO Annual Meeting

Trilaciclib, an intravenous CDK 4/6 inhibitor, in combination with Hycamtin may reduce chemotherapy-induced myelosuppression in small cell lung cancer, according to one expert.

Patients With Mantle Cell Lymphoma Experience Response to Imbruvica Combinations

Patients With Mantle Cell Lymphoma Experience Response to Imbruvica Combinations

June 27th 2019, 7:50pm

ASCO Annual Meeting

Newer treatments for MCL offer hope to patients living with the fast-growing and challenging-to-treat disease.

Targeted Therapies for Advanced MCL May Improve Outcomes as Front-line Treatment

Targeted Therapies for Advanced MCL May Improve Outcomes as Front-line Treatment

June 26th 2019, 8:00pm

ASCO Annual Meeting

Mantle cell lymphoma remains incurable, despite researchers’ best efforts. However, new treatment options show promise in the relapsed/refractory setting and may improve patient outcomes if moved to the front-line, according to Dr. Reem Karmali.

New Online Resources Provide Support to the Liver Cancer Community

New Online Resources Provide Support to the Liver Cancer Community

June 25th 2019, 10:00pm

ASCO Annual Meeting

The president and founder of Blue Faery: The Adrienne Wilson Liver Cancer Association discussed new initiatives and what’s on the horizon in the treatment of liver cancer.

Collection of Family Cancer History Is Suboptimal, Highlighting Need for Patient Reporting

Collection of Family Cancer History Is Suboptimal, Highlighting Need for Patient Reporting

June 24th 2019, 10:56pm

ASCO Annual Meeting

In assessing the quality of family cancer history entered into electronic health records, researchers found that such reporting was suboptimal – highlighting the need to optimize online collection with a provider-free approach.

Tumor Mutation Burden May Identify Those at Risk for Depression

Tumor Mutation Burden May Identify Those at Risk for Depression

June 24th 2019, 8:00pm

ASCO Annual Meeting

Increased tumor mutation burden (TMB), which is associated with more inflammation, may be a factor in determining which patients with lung cancer are at higher risk for depression.

Immuno-Oncology Initiative Seeks to Overcome Implementation Challenges

Immuno-Oncology Initiative Seeks to Overcome Implementation Challenges

June 21st 2019, 5:24pm

ASCO Annual Meeting

The growing use of immunotherapy in oncology has confronted many community practice-based oncologists with challenges to implementation, but one advocacy group’s new initiative aims to educate and empower.

How to Ease the Burden of Cancer Financial Toxicity

How to Ease the Burden of Cancer Financial Toxicity

June 19th 2019, 8:21pm

ASCO Annual Meeting

The financial navigation program at Taussig Cancer Institute provides patient assistance and helps them understand out-of-pocket costs.

Despite Advantages, Disparities in Access to Palliative Care in Kidney Cancer Remain

Despite Advantages, Disparities in Access to Palliative Care in Kidney Cancer Remain

June 19th 2019, 7:24pm

ASCO Annual Meeting

Although palliative care has been shown to improve survival rates among patients with metastatic renal cell carcinoma, its utilization remains low while certain barriers and disparities still exist.

Conversations on Patient Priorities and Preferences Should Take Place Before Treatment

Conversations on Patient Priorities and Preferences Should Take Place Before Treatment

June 14th 2019, 5:00pm

ASCO Annual Meeting

With so many cancer treatment options now available, clinicians may still fall short in understanding what’s important to patients.

Imbruvica Shows Promise as Maintenance Therapy for Patients With MCL

Imbruvica Shows Promise as Maintenance Therapy for Patients With MCL

June 13th 2019, 5:00pm

ASCO Annual Meeting

Maintenance therapy with Imbruvica appeared to be a feasible option for patients with mantle cell lymphoma, according to Dr. Reem Karmali.